Abbott Laboratories (ABT) Earnings History
Elite Compounder36 years of earnings data (1989–2024) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
Abbott Laboratories (ABT) Earnings Overview
As of June 22, 2026, Abbott Laboratories (ABT) reported trailing twelve-month net income of $13.98B, reflecting +133.6% year-over-year growth. The company earned $7.99 per diluted share over the past four quarters, with a net profit margin of 31.9%.
Looking at the long-term picture, ABT's 5-year EPS compound annual growth rate (CAGR) stands at +30.0%, indicating exceptional earnings growth. The company achieved its highest annual net income of $13.40B in fiscal 2024, representing a new all-time high.
Abbott Laboratories maintains industry-leading profitability with a gross margin of 50.8%, operating margin of 16.3%, and net margin of 31.9%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including MDT ($4.61B net income, 13.9% margin), BSX ($2.89B net income, 14.4% margin), BDX ($1.14B net income, 7.7% margin), ABT has outperformed on profitability metrics. Compare ABT vs MDT →
ABT Earnings vs Peers
Earnings metrics vs comparable public companies
ABT Historical Earnings Data (1989–2024)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $13.40B | +134.2% | $6.83B | $7.64 | 31.9% | 16.3% |
| 2023 | $5.72B | -17.5% | $6.43B | $3.27 | 14.3% | 16.0% |
| 2022 | $6.93B | -2.0% | $8.36B | $3.91 | 15.9% | 19.2% |
| 2021 | $7.07B | +57.3% | $9.20B | $3.94 | 16.4% | 21.4% |
| 2020 | $4.50B | +21.9% | $5.29B | $2.50 | 13.0% | 15.3% |
| 2019 | $3.69B | +55.7% | $4.59B | $2.06 | 11.6% | 14.4% |
| 2018 | $2.37B | +396.4% | $3.84B | $1.34 | 7.7% | 12.6% |
| 2017 | $477M | -65.9% | $1.97B | $0.27 | 1.7% | 7.2% |
| 2016 | $1.40B | -68.3% | $3.25B | $0.94 | 6.7% | 15.6% |
| 2015 | $4.42B | +93.7% | $2.95B | $2.94 | 21.7% | 14.5% |
| 2014 | $2.28B | -11.3% | $2.92B | $1.50 | 11.3% | 14.4% |
| 2013 | $2.58B | -56.8% | $2.15B | $1.64 | 11.8% | 9.8% |
| 2012 | $5.96B | +26.1% | $2.01B | $3.75 | 15.0% | 5.0% |
| 2011 | $4.73B | +2.2% | $6.84B | $3.01 | 12.2% | 17.6% |
| 2010 | $4.63B | -19.5% | $7.05B | $2.97 | 13.2% | 20.0% |
| 2009 | $5.75B | +17.7% | $6.57B | $3.70 | 18.7% | 21.4% |
| 2008 | $4.88B | +35.3% | $6.09B | $3.13 | 16.5% | 20.6% |
| 2007 | $3.61B | +110.1% | $4.95B | $2.31 | 13.9% | 19.1% |
| 2006 | $1.72B | -49.1% | $4.34B | $1.12 | 7.6% | 19.3% |
| 2005 | $3.37B | +4.2% | $4.65B | $2.16 | 15.1% | 20.8% |
| 2004 | $3.24B | +17.5% | $4.18B | $2.06 | 16.4% | 21.2% |
| 2003 | $2.75B | -1.4% | $2.97B | $1.75 | 14.0% | 15.1% |
| 2002 | $2.79B | +80.2% | $3.15B | $1.78 | 15.8% | 17.8% |
| 2001 | $1.55B | -44.4% | $1.89B | $0.99 | 9.5% | 11.6% |
| 2000 | $2.79B | +13.9% | $3.40B | $1.78 | 20.3% | 24.7% |
| 1999 | $2.45B | +4.8% | $3.15B | $1.57 | 18.6% | 23.9% |
| 1998 | $2.33B | +12.3% | $3.12B | $1.49 | 18.7% | 25.0% |
| 1997 | $2.08B | +10.5% | $2.85B | $1.33 | 17.5% | 24.0% |
| 1996 | $1.88B | +11.4% | $2.62B | $1.19 | 17.1% | 23.8% |
| 1995 | $1.69B | +11.3% | $2.38B | $1.06 | 16.9% | 23.8% |
| 1994 | $1.52B | +8.4% | $2.14B | $0.93 | 16.6% | 23.4% |
| 1993 | $1.40B | +12.9% | $1.92B | $0.84 | 16.6% | 22.9% |
| 1992 | $1.24B | +13.8% | $1.53B | $0.74 | 15.8% | 19.4% |
| 1991 | $1.09B | +12.7% | $1.56B | $0.64 | 15.8% | 22.6% |
| 1990 | $966M | +12.3% | $1.41B | $0.56 | 15.7% | 22.8% |
| 1989 | $860M | - | $1.22B | $0.49 | 16.0% | 22.7% |
Download Data
Export ABT earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into ABT consensus models and risk factors.
Should I Buy ABT?
Wall Street verdict, signals, and target summaries.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABT — Frequently Asked Questions
Quick answers to the most common questions about buying ABT stock.
What is ABT earnings per share (EPS)?
ABT trailing twelve-month (TTM) diluted EPS is $7.99, reflecting +133.6% year-over-year growth. The 5-year EPS CAGR is +30.0%. Complete EPS history from 1989 to 2024 is available in the table on this page.
What is Abbott Laboratories's net income?
Abbott Laboratories (ABT) trailing twelve-month net income is $14.0B as of 2024. Earnings grew +133.6% year-over-year. Abbott Laboratories has been profitable for 36 consecutive years.
Is ABT profitable?
Yes, ABT is profitable with a TTM net income of $14.0B and a net profit margin of +31.9%. Abbott Laboratories has generated profits for 36 consecutive years.
What is ABT's earnings growth rate?
ABT compound annual EPS growth rates (CAGR): 1-Year: +133.6%, 3-Year: +24.7%, 5-Year: +30.0%, 10-Year: +17.7%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2024.
What are ABT's profit margins?
Abbott Laboratories net profit margin is +31.9%, operating margin is +16.3%, and gross margin is +50.8%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +30.9%.
Is ABT growing earnings?
Yes, ABT earnings are accelerating — EPS growth of +133.6% exceeds the 5-year CAGR of +30.0%. TTM net income reached $14.0B. Earnings momentum is strengthening.
What was ABT's best earnings year?
Abbott Laboratories's highest annual net income on record is $13.4B, achieved in fiscal year 2024. Earnings history on this page spans 1989 to 2024 and includes all annual and quarterly figures.
What were ABT's earnings last quarter?
ABT's most recent reported quarter was Q3 2025. Net income was $1.6B with diluted EPS of $0.94. For a full breakdown of all quarters, see the quarterly earnings table on this page.